RE:RE:RE:RE:RE:RE:RE:money questionsDog, you forgot that the current phase 2 data is marching along as planned, 180 days from now the 450 day column is going to look alot more like the recent 270 day column. The market is going to notice that sometime. Probably b4 the end of that 180 days.... ;-)
DJDawg wrote:
We are all in the same boat. (Including RDW I guess, since he is a large longholder and he follows this board).
On the inspiring side
- solid science to start with (go Dr. McFarland!)
- trials and data integrity supervised by Clinician investigators rather than company staff.
- phase 1b results 2 patients that were 1 and done
- that someone at TLT found a way to insert TLD-1433 into work at the NML. Takes some networking and good science to do that
- that TLT got free lab support from Li Ka Shin Institute. Few private Biotechs have that.
- that the current data beats Keytruda benchmark.
- that Rutherrin is coming (could argue that the patents on that are possibly worth more than the company at the moment).
- RDW and spouse buying large amounts of shares over the years and not selling
- reasonably efforts at patent securing around the globe.
On the less inspiring side
- patterns of staff exits (Sherazi, Vera, Trikola)
- mess up on the first 12 patients underdosed (maybe that was more to do with the science being so knew and hard to figure out rather than blaming TLT)
- decision to chase internet trolls with lawsuits
- lack of stock movement over such a long period of time
- lack of visible progress on IV Rutherrin for GBM and NSLC towards human trials
- the current cash runway.
Feel free to add to my two lists if you can think of more things.
I continue to hold for the science but not easy at times.
(RDW - please find a way to boost our confidence).